Imunon (IMNN) Cash from Investing Activities (2010 - 2025)
Imunon's (IMNN) quarterly Cash from Investing Activities came in at -$3589.0 in Q4 2025, up 75.92% YoY from -$2040.1 in Q4 2024, and up 79.29% on a QoQ basis from -$17331.0 in Q2 2025.
Imunon (IMNN) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Imunon (IMNN) has 16 years of Cash from Investing Activities data on file, last reported at -$3589.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 75.92% year-over-year to -$3589.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$280572.0 (down 102.85% YoY) and the FY2025 annual result came in at -$280572.0, down 102.85% from the prior year.
- Cash from Investing Activities advanced to -$3589.0 in Q4 2025, from -$17331.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $16.8 million in Q1 2022 to a low of -$17.0 million in Q2 2021.
- A 5-year average of -$67751.4 and a median of -$3589.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 18734.29% — and 2024, when it surged 472.39%.
- Tracing IMNN's Cash from Investing Activities over 5 years: stood at -$974486.0 in 2021, then tumbled by 1017.0% to -$10.9 million in 2022, then surged by 69.65% to -$3.3 million in 2023, then surged by 99.55% to -$14907.0 in 2024, then soared by 75.92% to -$3589.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$3589.0 (Q4 2025), -$17331.0 (Q2 2025), and -$259652.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3,589.00 |
| Dec 31, 2025 | -3,589.00 |
| Jun 30, 2025 | -17,331.00 |
| Jun 30, 2025 | -17,331.00 |
| Mar 31, 2025 | -259,652.00 |
| Mar 31, 2025 | -259,652.00 |
| Dec 31, 2024 | -14,907.00 |
| Dec 31, 2024 | -14,907.00 |
| Sep 30, 2024 | -2,879.00 |
| Sep 30, 2024 | -2,879.00 |
| Jun 30, 2024 | 7.46 Mn |
| Jun 30, 2024 | 7.46 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Dec 31, 2023 | -3.30 Mn |
| Dec 31, 2023 | -3.30 Mn |
| Sep 30, 2023 | 10.67 Mn |
| Sep 30, 2023 | 10.67 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Jun 30, 2023 | 3.23 Mn |